Magnetic resonance imaging (MRI) is used to image the slow flow of cerebrospinal fluid (CSF) in subarachnoid and perivascular spaces, amongst other regions of the brain and central nervous system. The slow CSF flow imaging can be provided by using low velocity' encoding (VENC) and an efficient data acquisition. Tailored image processing can be used to further improve the accuracy, specificity, and visualization of CSF flow dynamics.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G16H 30/00 - ICT specially adapted for the handling or processing of medical images
2.
SYSTEM AND METHOD FOR CONTROL OF IONIZING RADIATION DOSE IN MEDICAL APPLICATIONS USING SYNTHETIC LOCALIZERS
Methods, system, and non-transitory media are provided for tube-current-modulation (TCM) calculation in computed tomography (CT) imaging. The radiation dose exposure is adjusted by identifying dose varying anatomical markers such as arms or removable objects that are not consistently positioned between localizer and actual scanning. Provided herein are means of reducing the effect of those anatomical markers on the TCM calculation by generating a synthetic localizer from an acquired localizer of a patient wherein the anatomical marker has been modified to match the actual scanning status. Modification of the dose-varying anatomical marker may include changing the position from an arms-down to arms up position or complete image signal removal of the arms or other markers from the localizer.
Described herein are methods and compositions for treating Alzheimer's Disease (AD), as well as compositions comprising a reelin-derived peptide and methods of use thereof.
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Formulations of HDAC6 inhibitors passing through the blood brain barrier in hypothalamus and inhibiting HDAC6 in the arctuate AgRP neurons in the hypothalamus, are effective to cause weight loss in obese individuals. These inhibitors also restore leptin sensitivity in leptin-resistant individuals.
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/505 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
One or more devices, systems, methods, and storage mediums for performing robotic control and/or for performing localization and lesion targeting are provided herein. Examples of such control, localization and lesion targeting include, but are not limited to, correction of one or more sections or portions of a continuum robot as the continuum robot is moved and performing localization and lesion targeting in a bronchial pathway using a continuum robot. Examples of applications include imaging, evaluating, and diagnosing biological objects, such as, but not limited to, for bronchial applications, and being obtained via one or more optical instruments, such as, but not limited to, optical probes, catheters, endoscopes, and bronchoscopes. Techniques provided herein also improve processing, imaging, and lesion targeting efficiency while achieving images that are more precise, and also achieve devices, systems, methods, and storage mediums that reduce mental and physical burden and improve ease of use.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
A61B 34/00 - Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
6.
ENGINEERED BIFUNCTIONAL RECEPTORS AND USES THEREOF
Described in several example embodiments herein are engineered bifunctional receptors that can include an E3 ligase binding domain and a target binding domain operatively coupled to the E3 ligase binding domain. In some embodiments, the engineered bifunctional receptors are capable of targeted degradation of a target protein. Also described in several example embodiments herein are compositions, formulations, and cells that can include or generate the engineered bifunctional receptors and uses thereof.
The present document relates to covalent compounds and uses thereof, including methods of targeting or engaging one or more targets with a covalent compound. Also provided herein are methods of treating a disease using such a compound and methods of identifying one or more targets using such a compound.
C07C 233/11 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
8.
IMMUNOCAPTURE METHODS TO ENRICH FOR ENGINEERED EXTRACELLULAR VESICLES
Extracellular vesicles (EVs) are natural liposome-like vesicles secreted by cells into the extracellular space. Provided herein are techniques to enrich cargo-loaded EVs over non-loaded EVs and contaminants. To achieve EVs were engineered to display their surface an antigenic tag for fast and efficient EV isolation by immunocapture and a fluorescent protein in the internal space of the EV. Cargo was loaded into the lumen of the EVs by fusing the cargo with an antibody or nanobody that has an affinity for the fluorescent protein of the internal space. To prevent potential antigenicity of the EVs, a TEV cleavage site was included allowing the removal of exposed antigenic tag from immunocaptured EVs, while preserving their luminal cargo.
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
Accelerated time-resolved multi-echo magnetic resonance imaging (MRI) uses augmenting of the temporal correlation across echoes, for example, by applying gradient blips that sample the spatiotemporal space in a new trajectory to reduce dead time and echo spacing. Additionally or alternatively, acceleration may be achieved by optimization of the encoding pattern to reduce temporal distance and/or using a spatiotemporal partial Fourier acquisition.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G16H 30/00 - ICT specially adapted for the handling or processing of medical images
10.
METHOD AND SYSTEM FOR MOTION-ROBUST SUPER-RESOLUTION MAGNETIC RESONANCE IMAGING
The present disclosure provides a method for generating MRI images of a subject. The method includes accessing MRI images of the subject that have a first resolution, where each of the MRI images was acquired with a selected sampling pattern. The method further includes estimating motion between the MRI images to determine a motion transformation that corresponds to motion of the subject between the MRI images. The method further includes applying a model-based super-resolution reconstruction to the MRI images. The reconstruction accounts for the motion transformation and generates an image of the subject within the image volume that has a second resolution greater than the first resolution.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G16H 30/00 - ICT specially adapted for the handling or processing of medical images
11.
LIBRARY-SCALE METHODS FOR POLYPEPTIDE FUNCTIONAL ANALYSIS
Disclosed herein are methods, compositions, systems, and kits related to functional testing of polypeptide-target interactions, such as antigen/immune receptor interactions, in a single-cell format.
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
12.
SYSTEM AND METHOD FOR MULTIPHOTON PARALLEL TRANSMIT EXCITATION FOR MRI
A method for generating a magnetic resonance image of a subject using a magnetic resonance imaging (MRI) system includes receiving, using the MRI system, at least one parameter for a multiphoton parallel transmit excitation comprising a multiphoton excitation pulse configured to correct spatial inhomogeneities and performing, using the MRI system, a pulse sequence comprising the multiphoton parallel transmit excitation to acquire data from the subject. The multi photon excitation pulse of the multi photon parallel transmit excitation is performed using a radio frequency (RF) coil and a set of one or more shim coils of the MRI system. The method further includes generating, using a processor, an image of the subject using the acquired MR data. In some embodiments, the multiphoton excitation pulse includes an off-resonance RF excitation pulse performed using the RF coil and a plurality of low-frequency excitation pulses performed using the set of one or more shim coils. The plurality of low-frequency excitation pulses are performed simultaneously with the off-resonance RF excitation pulse.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G16H 30/00 - ICT specially adapted for the handling or processing of medical images
13.
MINIMALLY INVASIVE DEVICE FOR NERVE IDENTIFICATION, STIMULATION, AND MANIPULATION
Systems and methods for an insertable medical device are described. The device comprises a device body configured to be insertable into a subject; proximal and distal openings; a cavity extending through the device body and in communication with the proximal opening and the distal opening, the cavity and the proximal opening being dimensioned to receive an instrument therein; a plurality of electrically conductive pads configured to be positioned a predetermined location relative to the proximal and distal openings, and configured to sense an electrical characteristic of the subject; an I/O device configured to: output signal data from the electrically conductive pads to a processing device operating a ML algorithm, the signal data including data corresponding to the electrical characteristic of the subject, and receive response data generated by the ML algorithm indicating a tissue type proximate respective electrically conductive pads based on an analysis of the signal data.
A radiation oncology workflow management system is provided. The system may include interactive graphical interface and a particularly programmed processor, thereby to perform operations including displaying a window containing a user interface (UI) environment on a computer screen, parsing an input received from a user via the UI environment, thereby to determine which of a plurality of atomic application functions is indicated by the input, automatically interacting with an atomic application associated with the atomic application function determined to be indicated by the input, and automatically displaying information received from the atomic application via the UI environment.
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
15.
METHODS AND COMPOSITIONS FOR HIGH-THROUGHPUT DISCOVERY OFPEPTIDE-MHC TARGETING BINDING PROTEINS
The present invention discloses methods and platforms for generating protein binding proteins with specificity for native peptide-MHC (pMHC) complexes. The pMHC binding proteins can be used in bi-specific antibodies or for generating CAR T cells capable of binding to peptides bound to specific MHC alleles.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
16.
ARTIFICIAL INTELLIGENCE ENABLED DISCRIMINATION OF DISEASE AND DISEASE ETIOLOGY
The subject matter disclosed herein relates using waveform data of a subject to detect one or more diseases or disease etiologies. Particular examples relate to providing a system, a computer-implemented method, and a computer program product to waveform data to detect and differentiate particular diseases and disease etiologies with machine learning models.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
17.
MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS (OHSV) AND METHODS OF USE THEREOF
Described herein is an oncolytic herpes simplex virus, G47ΔhIL12A, which is G47Δ containing a cassette expressing a transgene, e.g., human IL-12, driven by a spontaneously arising genetically altered HCMV immediate-early (IE) enhancer/promoter. This virus has augmented (A) production of the transgene and increased virus replication while retaining safety. Also provided are methods of use thereof for treating cancer, e.g., glioblastoma (GBM) and triple-negative breast cancer (TNBC).
18.
ADMINISTRATION OF GLUTATHIONE TRISULFIDE TO AMELIORATE PERIPHERAL NEUROPATHY
Methods and devices for the administration of compositions comprising glutathione trisulfide (GSSSG), pantethine trisulfide (PTN-SSS), or lipoic acid trisulfide (LA-SSS) to treat peripheral neuropathy, e.g., chemotherapy-induced peripheral neuropathy (CIPN), e.g., by oral or nasal administration. The methods can be used, e.g., to reduce pain associated with CIPN, or reduce the risk of development of CIPN.
19.
4-1BBL AND IL-12 THERAPY FOR TREATMENT OF GLIOBLASTOMA
Provided herein are methods of treating glioblastoma including administering to a subject having glioblastoma a therapeutically effective amount of a pharmaceutical composition comprising 4-1BBL, optionally in combination with recombinant IL-12. The 4-1BBL can be provided to the subject via an adeno-associated virus, for example AAV-F, and the IL-12 can be provided by intratumoral injection.
20.
PROBES AND METHODS TO IDENTIFY LIGANDABLE FATTY ACYLATION SITES FOR THERAPEUTIC TARGET IDENTIFICATION
The present disclosure relates to compounds of Formula I and methods comprising the use of these compounds to identify ligandable fatty acylation sites.
21.
SYSTEM AND METHOD FOR DETERMINING PERFUSED TISSUE VIABILITY
The disclosure provides perfusion systems and methods for continuous or intermittent perfusion to monitor and extend the viability of tissue for transplants. Intermittent perfusion involves generating perfusion cycles which alternate between baseline and high oxygen gas partial pressure in the circulating perfusate. The system comprises a perfusion fluid source and an inflow conduit in fluid communication with the perfusion fluid source and a tissue sample, wherein the inflow conduit is configured to deliver perfusion fluid to the tissue sample. The system further comprises an outflow conduit in fluid communication with the tissue sample, wherein the outflow conduit is configured to carry perfusion fluid away from the tissue sample. A first gas sensor is in fluid communication with the inflow-conduit and measures a. concentration of a gas in perfusion fluid, in the inflow conduit, and a second gas sensor is in contact with the tissue sample and measures a concentration of a gas in the sample.
22.
GENE THERAPY FOR GENETIC AND ACQUIRED VASCULOPATHIES
Described herein are gene-targeted therapies and compositions that can include a vessel-specific viral vector, preferably in combination with a HDAC9-derived promoter to transduce SMC and deliver a base editor that corrects mutant alleles or a Cas nuclease that knocks out the mutant allele.
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
23.
METHODS FOR TREATMENT SELECTION FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
As described below, the present invention features compositions, panels of biomarkers, and methods for selecting a subject with chronic lymphocytic leukemia (CLL) for treatment using an agent and/or for inclusion in a clinical trial using the agent to treat CLL.
The disclosure presents a shaftless, brushless motor for rotating any optical or sensing element (e.g., a lens or mirror) at a distal end of a waveguide that also delivers electromagnetic radiation (e.g., light). Herein, the waveguide itself functions as the axle on which rotating components rotate, thereby avoiding blind spots and overcoming limitations in existing "micromotors". The shaftless, distally driven motor significantly reduces motor size, while extremely small inertial loads and bearing sizes allow for high pitch cylindrical scanning with longitudinal velocity uniformity.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
G02B 6/00 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
26.
METHOD AND APPARATUS FOR MODULATING SIGNALS OF LUMINESCENT POLYMER/DYE FORMULATIONS USING LIGHT SCATTERING PARTICLES
A sensing system and method for sensing an analyte. The sensing system includes; a sensing material having one or more layers, the sensing material including; a light emitting material and a plurality of signal enhancing particles disposed within a polymer matrix. The sensing method includes: providing a sensing material including one or more layers, the sensing material including a light emitting material and a plurality of signal enhancing particles disposed within a polymer matrix, the light emitting material being sensitive to an analyte; exposing the sensing system to the analyte; and measuring a change in a light emission from the light emitting material based on exposing the sensing system to the analyte.
G01N 21/27 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (United Kingdom)
THE GENERAL HOSPITAL CORPORATION (USA)
Inventor
Kleinstiver, Benjamin
Guy, Jacqueline
Bird, Adrian
Abstract
The present disclosure relates to compositions for use in the treatment of a class of Rett syndrome mutations, namely C-terminal deletions, comprising a base editor to alter a stop codon in a mutant MECP2 gene. This alteration does not return the gene to its wild-type (WT) form, but re-establishes normal levels of a version which is functionally equivalent to a wild¬ type version of the MeCP2 protein.
Disclosed are supramolecular hybrid hydrogels (SHH), wound dressings, comprising supramolecular hybrid hydrogels; and methods of treating wounds, including burns.
A61F 13/00 - Bandages or dressings; Absorbent pads
A61L 15/22 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages
29.
SYSTEMS AND METHODS FOR ATTENUATING ACOUSTIC WAVES
An acoustic filter can include a first substrate including a first plurality of holes directed, therethrough, a second substrate including a second plurality of holes directed therethrough, a chamber defined between the first substrate and the second substrate, and a membrane positioned within the chamber. The membrane can have a dimension other than the thickness of the membrane that can be less than a corresponding dimension of the chamber. The acoustic filter can be configured to attenuate a first acoustic wave that passes through the acoustic filter, the first acoustic wave can have a first amplitude above an amplitude threshold. The acoustic filter can be configured to passthrough a second acoustic wave without substantially attenuating the second acoustic wave, the second acoustic wave can have a second amplitude below' the amplitude threshold.
Described herein are perfusable 3D tubule-on-chip models comprising at least one tubule consisting of one patent lumen circumscribed by organoid- derived cells, and a multifluidic platform comprising at least one individually addressable chip. The models may further include an unseeded tubule, where the seeded tubule and the unseeded tubule are co-localized on the chip, and wherein the tubule and the unseeded tubule are embedded within a gelatin-fibrin extracellular matrix (ECM). Also, described here are methods of producing the described perfusable 3D tubule-on-chip models, and uses of the same.
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
Provided herein are computer-implemented methods for assigning maternal or fetal origin to one or more genetic variants in cell free DNA (cfDNA) from a sample from a pregnant mammal, preferably a pregnant human, using a probabilistic model for assigning maternal or fetal origin to genetic variants in DNA from a sample obtained from a pregnant mammal, wherein the model assigns maternal or fetal origin based on a combination of fetal fraction and DNA fragment size.
C12Q 1/6804 - Nucleic acid analysis using immunogens
G16B 40/00 - ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
32.
COMPOSITIONS AND METHODS FOR TREATING TRINUCLEOTIDE REPEAT DISORDERS
Methods and compositions for reducing expansion of nucleotide repeats in a cell, comprising base editors and a guide RNA (gRNA) that directs the Cas-based enzyme to the splice acceptor site for mutL homolog 3 (MLH3) exon 7 or to the MLH3 endonuclease domain.
C12N 15/75 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
33.
METHODS AND COMPOSITIONS FOR PROGNOSIS AND TREATMENT OF DILATED CARDIOMYOPATHY AND HEART FAILURE
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
34.
INJECTABLE THERMOSENSITIVE HYDROGELS FOR A SUSTAINED RELEASE OF IRON NANOCHELATORS
Disclosed herein are injectable hydrogel formulations prepared by integrating crosslinked hyaluronic acid into Pluronic F127 for an extended release of DFO nanochelators. Methods of manufacture and of use are also provided.
Disclosed herein are implantable vascular devices and methods of use thereof. Exemplary embodiments of the implantable vascular device comprise a tubular stent component, and one or more of a cell compartment, a graft component, or a bioscaffold, along with one or more support members providing a fixed position between the tubular stent component and the cell compartment, graft component, or bioscaffold. Preferably, the one or more support members provide a collapsible fixed position. Methods of use include methods of implanting and methods of removing, the device, as well as methods of reseeding the device, in some embodiments.
A device for carbon dioxide monitoring is disclosed. The device comprises: a photoluminescent carbon dioxide-sensitive probe comprising a polymer matrix and a sensing dye; a photon source configured to direct photons at the probe; a photodetector configured to detect light emitted from the probe when the photon source directs photons at the probe; a carbon dioxide permeable light redirection layer, wherein the carbon dioxide-sensitive probe is positioned between the light redirection layer and the photodetector; and a controller in electrical communication with the photon source and the photodetector, the controller being configured to execute a program stored in the controller to calculate a level of carbon dioxide adjacent the probe from an electrical signal received from the photodetector. In one form, the polymer matrix comprises a polymer selected from the group consisting of acrylate polymers, methacrylate polymers, polyurethane polymers, and blends and copolymers thereof.
A61B 5/1459 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
G01J 1/58 - Photometry, e.g. photographic exposure meter using luminescence generated by light
G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroups; Apparatus specially adapted for such methods using chemical indicators
A system for performing retrograde tethered capsule endomicroscopy, including: a capsule including at least one outwardly-facing helical thread; a drive shaft coupled to the capsule and configured to rotate the capsule; and an optical system disposed within the capsule and configured to obtain circumferential imaging information. A method for performing retrograde tethered capsule endomicroscopy, comprising: providing a capsule comprising at least one outwardly-facing helical thread and an optical system disposed within the capsule; rotating the capsule using a drive shaft coupled to the capsule; and obtaining circumferential imaging information using the optical system disposed within the capsule.
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
A61B 1/07 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with illuminating arrangements using light-conductive means, e.g. optical fibres
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
Methods, systems, and apparatus, including computer programs encoded on computer storage media, for proteome mapping. One of the methods includes: identifying one or more target peptide sequences for a sample; estimating an elution order of one or more expected peptides from a chromatography column; and initiating generation of a first set of mass spectrometry spectra for the sample. The method also includes detecting peaks within the first set of mass spectrometry spectra to determine a real-time status with respect to the estimated elution order; selecting one or more peptide ions that are (i) observed in the first set of mass spectrometry spectra and (ii) included among the one or more peptides expected to be present in the sample; and initiating generation of a second set of mass spectrometry spectra for the one or more selected peptide ions.
A biosensor cartridge is disclosed. The biosensor cartridge, which detects biological material so as to generate an electrochemiluminescence signal, according to one aspect of the present invention, comprises: an electrode unit including a plurality of electrodes; and a dividing unit disposed on the electrode unit so as to divide the entire space provided on the electrode unit into a signal chamber and N-number of reaction chambers, which encompass the signal chamber, wherein the electrode unit includes a first electrode of which at least a portion is disposed in the reaction chambers, a second electrode disposed in the signal chamber, and N-number of connection electrodes disposed to electrically link the chemical reaction in the reaction chambers and the electrochemiluminescence signal generated in the signal chamber.
G01N 21/66 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light electrically excited, e.g. electroluminescence
Methods for increasing expression of a target gene, the method comprising introducing a CCCTC-binding factor (CTCF) binding site (CTCF-BS) into a promoter region of the target gene, e.g., within 500, 250, 200, 150, 100, 50, or 25 nucleotides of the transcription start site (TSS) for the target gene, and optionally expressing in or introducing into the cell a CTCF protein or variant thereof.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Systems, methods, and devices are described herein for use in detecting and/or monitoring target extracellular vesicles ("EVs"), e.g., to detect and/or monitor treatment for a disease, e.g., for cancer, in a subject. The systems can include nano-plasmonic arrays of nanostructures arranged to form a periodic array on a substrate, and each nanostructure can include a nanopillar, a spacer layer, e.g., coated onto a metallic layer, and a plurality of metal nanoparticles bound to each of the nanopillars. The nano-plasmonic arrays amplify specific wavelengths of electromagnetic radiation and can be used to capture and image target EVs.
G01N 21/63 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
G01N 15/02 - Investigating particle size or size distribution
Provided herein are compositions and methods of use thereof for treating Autosomal recessive polycystic kidney disease (ARPKD) by targeting Rac family small GTPase 1 (RAC1 ) and/or Fos proto-oncogene, AP-1 transcription factor subunit (FOS) by administering a therapeutically effective amount of an inhibitor of RAC1 and/or FOS to a subject in need thereof.
T cell responses are exquisitely antigen-specific and directed against peptide epitopes displayed by human leukocyte antigen (HLA) on the surface of presenting cells. In particular, class II HLA (HLA-II) is remarkably polymorphic, which allows for presentation of diverse peptide antigens to T cells, but also forms the basis for genetic associations with diverse immunopathologies across the spectrum of infectious disease and autoimmunity. Here, Applicants employ monoallelic immunopeptidomics to retrieve over 200,000 unique peptides presented by 41 HLA-II heterodimers covering major alleles across diverse ancestries. Applicants leveraged this expansive dataset to develop computational models that predict peptide antigens based on HLA-II binding properties and infer informative features of the protein antigens from which these peptides derive. Combining both peptide and (contextual) protein features, Applicants develop Context Aware Predictor of T cell Antigens (CAPTAn) to discover novel T cell epitopes from prokaryotes in the human microbiome and the viral pandemic pathogen SARS-CoV-2.
Systems and methods are provided for forming a system for transmitting electrical signals to or from the head of a subject. The system includes a base layer. A layer of conductive, non-ferrous material may be deposited along an upper surface of the base layer using a thin-film deposition technique, which is patterned into a conductive trace that extends between a proximal end and a distal end of the base layer. A thick film forming an electrode is positioned relative to a distal end of the conductive trace.
An apparatus and method for removing dermal tissue from a dermis layer. The apparatus can include a hollow needle with a proximal end, a distal end, and a central lumen extending from the proximal end through the distal end. Properties of the hollow needle can be selected such that the hollow needle can be inserted into dermal tissue to remove a portion of tissue from a transplant site in preparation for the insertion of a hair follicle from a donor site. Some apparatus can include a plurality of hollow needles and/or a reciprocating arrangement to mechanically advance and withdraw the one or more hollow needles.
The present disclosure provides bicyclononyne based compounds and methods to prepare an antibody conjugate with a fluorophore, as well as the methods of using these conjugates for cellular imaging. In one example, the conjugate may be coupled with a quencher to absorb fluorescence from the fluorophore.
C07C 13/45 - Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with a bicyclo ring system containing nine carbon atoms
C07C 211/19 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing condensed ring systems
C07C 229/28 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
48.
COMPOSITIONS AND METHODS FOR CONTROL OF TRANSIENT SITE-SPECIFIC COPY GAINS, GENOMIC INSERTIONS, AND REARRANGEMENTS ASSOCIATED WITH MIXED LINEAGE LEUKEMIA
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 15/52 - Genes encoding for enzymes or proenzymes
A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
49.
SYSTEM FOR AND METHOD OF MEASURING BLOOD PRESSURE NON-INVASIVELY WITH LIGHT
Optical patient monitoring systems are disclosed. The system may comprise an optical coupling system configured to transmit to and receive light signals from one or more locations on a subject; an optical processing system configured to generate optical data using the received light signals; and a computer programmed to receive the optical data; determine, using the optical data, at least one indicator of blood pressure; estimate an estimated blood pressure using the at least one indicator of blood pressure; and generate a report indicative of the estimated blood pressure. The at least one indicator of blood pressure comprises one or more of near-infrared spectroscopy (NIRS) data; photoplethysmography (PPG) data, diffuse correlation spectroscopy (DCS) data, speckle contrast optical spectroscopy (SCOS) data, speckleplethysmography (SPG) data, first derivative PPG data, second derivative PPG data, first derivative SPG data, second derivative SPG data, inflow (Fin) data, outflow (Fout) data, heart rate data, physiological data, and combinations thereof. Methods for estimating blood pressure are also disclosed.
A61B 5/021 - Measuring pressure in heart or blood vessels
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value using optical sensors, e.g. spectral photometrical oximeters
A61B 5/318 - Heart-related electrical modalities, e.g. electrocardiography [ECG]
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A system for identifying a plurality of biomarkers in a sample, including: a substrate including a plurality of microneedles projecting therefrom, each of the plurality of microneedles including a plurality of biomarker recognition molecules attached thereto, and the plurality of microneedles including a first microneedle and a second microneedle, the first microneedle including a first plurality of biomarker recognition molecules configured to recognize a first biomarker, and the second microneedle including a second plurality of biomarker recognition molecules configured to recognize a second biomarker different from the first biomarker.
An eyelid treatment system can include a contact lens that can include an inner concave surface and an outer convex surface opposite the inner concave surface. The contact lens can be configured to be placed on an eyeball of a subject. The eyelid treatment system can include a light source optically coupled to the contact lens. The light source can be configured to deliver light to an inner surface of an eyelid of the subject when the contact lens is placed on the eyeball. The inner concave surface can be configured to at least partially block light from being transmitted through the inner concave surface, such that the light propagates in a direction away from the eyeball of the subject. The light from the light source can be configured to reduce eyelid inflammation.
Antibodies, and antigen-binding fragments thereof, that specifically bind to bone morphogenetic protein-9 (BMP9) are provided. Embodiments include uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.
In some aspects, the present disclosure provides a method for determining a risk or state of a neurodegenerative disease of a subject. In some embodiments, the method comprises detecting a presence of a biomarker in a biological sample from the subject, wherein the biomarker comprises at least one of: E7EUF1, O94812, P02549, P02730, P05019, P05154, P05546, P13497, P16157, P16452, P17936, P24593, P27918, P35858, P41218, Q12797, Q13214, Q13822, Q8NI99, Q96IY4, Q99715, Q9BXN1, Q9H0B8, or a proteoform thereof. In some embodiments, the method comprises detecting a presence of a biomarker in a biological sample from the subject, wherein the biomarker comprises at least one of: P54803, P14625, P30043, P00742, A0A0D9SG88, Q5TFM2, P54803, P54803-3, P54803-4, P04196, or a proteoform thereof. In some embodiments, the method comprises determining the risk or state of the neurodegenerative disease of the subject based on the presence of the biomarker in the biological sample.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
57.
METHODS OF IDENTIFYING GENETICALLY-ANCHORED MOLECULAR SIGNATURES FOR DISEASE AND TREATMENTS THEREOF
The present invention provides a method for obtaining genetically-anchored molecular signatures that are molecular signatures linked to genetic risk variants and that define mechanistic disease pathways in order to facilitate improved disease sub-classification, develop of novel rational therapeutics, and implement targeted prevention practices. The signatures can be obtained using polygenic risk scores and gene expression data, such as partitioned polygenic risk scores. In certain embodiments, the method further comprises identifying one or more key regulatory features of the genetically-anchored molecular signature by matching the genetically-anchored molecular signature with one or more perturbation molecular signatures from a perturbation data set using similarity scoring
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Devices and methods for improving the infection-healing behavior of a biological wound are disclosed. The device can comprise: a matrix; a light-emitting layer comprising a plurality of light sources; a controller in electrical communication with the light sources, the controller being configured to execute a program stored in the controller to activate the light sources to irradiate the wound or a region adjacent the wound with light for a period of time when the device is placed over the wound; and an antimicrobial adjuvant present as part of the device in an amount effective to synergistically potentiate antimicrobial activity of the light with respect to microbes on or adjacent the wound. The wound may include microbes in a biofilm. In one embodiment, the antimicrobial adjuvant comprises a substituted naphthalene, such as menadione. In one embodiment, the antimicrobial adjuvant comprises near infrared radiation.
Described herein are methods for treating a carcinoma in a subject, the method comprising administering to the subject a therapeutically effective amount of (5z)-7-oxozeaenol (Oxo) or an analog thereof, optionally in combination with chemotherapy.
Described herein are methods and compositions for treating neurodegenerative diseases including Spinocerebellar Ataxia comprising administering a BACE1 inhibitor.
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
A61K 31/549 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Disclosed is a system for imaging of microvasculature of tissue of a subject. The system can comprise: (a) a tissue stabilizer structured to contact the tissue of the subject to maintain a position of the region of microvasculature being imaged, and (b) an imaging instrument including: (i) a housing having an imaging section, (ii) an illumination device having a light-outputting end positioned in the imaging section for illuminating a region of the microvasculature with light, wherein the light-outputting end is offset relative to an optical axis of the imaging section; (iii) an objective lens positioned in the imaging section such that the objective lens receives at least a portion of light scattered by the region of the microvasculature, and (iv) an image detector positioned in the imaging section such that the image detector receives light redirected by the objective lens and detects microscopic images of the region of microvasculature.
62.
METHODS AND COMPOSITIONS FOR IMMUNE CELL CRISPR SCREENS
Disclosed are devices and methods for treating a skin condition (e.g., cutaneous neurofibroma tumors) of a subject. The device comprises: a chamber having an end wall, a side wall extending away from the end wall, and an opening opposite the end wall, wherein the side wall terminates in a contact surface for sealing against skin of a subject; a vacuum source in fluid communication with the interior space of the chamber, the vacuum source being structured to create negative pressure in the chamber; and a light source for irradiating a region of the skin of the subject with light, the light source being selected from the group consisting of laser light sources and wavelength-filtered light sources, the light source being positioned to direct the light at the region of the skin of the subject when the light source is activated to treat the skin condition.
A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
A61M 1/00 - Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
A61N 5/067 - Radiation therapy using light using laser light
64.
TREATMENT AND DETECTION OF CANCERS HAVING A NEURAL-LIKE PROGENITOR, SQUAMOID/BASALOID/MESENCHYMAL, OR CLASSICAL PHENOTYPE
The subject matter disclosed herein is generally directed to methods of detecting treatment refractory cancer and treatment thereof In example embodiments, specific biomarkers expressed specifically in pancreatic cancer subtypes are disclosed. The biomarkers can be used for therapeutic targeting of pancreatic cancers. The biomarkers can be used for noninvasive diagnostic methods.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Methods and devices for the nasal administration of compositions comprising glutathione trisulfide (GSSSG), pantethine trisulfide (PTN-SSS), or lipoic acid trisulfide (LA-SSS) in neuroprotection, e.g., in neurodegenerative diseases and to reduce the risk of ischemic injury. The methods can be used, e.g., to reduce risk of injury to brain, spinal cord, and peripheral nerves from ischemia or low blood flow states possibly caused by surgery, trauma, and other conditions that decrease/impair blood flow and or oxygen delivery to the nervous system.
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 5/02 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
The present disclosure relates to direct immobilization of antibodies by physisorption onto plain and nanostructured metal-containing films. An exemplary method for preparing a sensor includes contacting an antibody with a surface of a film comprising an ionic compound and a metal selected from gold, silver, platinum, copper, and any combination thereof, and then contacting a blocking agent with the surface of the film to form the sensor.
The present disclosure relates to drug-conjugate molecules that release a biologically active payload upon exposure to ionizing radiation. Localized x-ray irradiation releases the payload under normoxic and/or hypoxic conditions that are traditionally associated with radiotherapy resistance.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/51 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
Disclosed is a method for regenerating and/or repairing lung tissue in a subject. The method comprises administering to a subject in need of lung tissue regeneration and/or repair a composition including (i) a carrier comprising a scaffold-forming material, (ii) cellular material selected from the group consisting of endothelial cells, epithelial cells, mesenchymal stem cells, and mixtures thereof, and (iii) pneumocytes. In one embodiment of the method, the administering is intravenously or intratracheally. The administering can be via airways to the lung. The scaffold-forming material can comprise (i) a first biopolymer having a first reactive group; (ii) a second biopolymer having a second reactive group, wherein the first reactive group and the second reactive group react via click chemistry to crosslink the first biopolymer and the second biopolymer to form a hydrogel; (iii) a porogen; and a (iv) porogen-degrading agent.
Provided herein are compositions, kits, and methods of making biodegradable compositions for localized drug delivery. The drug delivery compositions include one or more therapeutic agents that are dispersed within polymerized macromers of the drug delivery composition, loaded within biopolymeric nanoparticles within the drug delivery composition, or both. The release profiles of the one or more therapeutic agents are tunable based on the one or more therapeutic agents for a desired application.
A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
A system and method for flow sorting includes a sample loader that is configured to receive a sample that contains one or more laser microparticles, wherein each laser microparticle is configured to generate laser emission with one or more distinct spectral peaks when excited. The system further includes a spectrometer receiving the laser emission from the one or more laser microparticle and generating spectral data and a processor configured to receive the spectral data and generate a sorting signal. The system also includes a switch configured to receive the sorting signal and route the one or more microparticles to a particular one of multiple collection channels based on the sorting signal.
The disclosure features compositions containing chimeric antigen receptor (CAR) immune cells that have been modified to reduce and/or eliminate expression or activity of a natural killer cell lectin A (NKG2A) polypeptide and/or a cluster of differentiation 94 (CD94) polypeptide, and methods for use thereof to treat a neoplasia.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
72.
SYSTEM FOR AND METHOD OF PLANNING AND REAL-TIME NAVIGATION FOR TRANSCRANIAL FOCUSED ULTRASOUND STIMULATION
A system for planning and real-time navigation for transcranial focused ultrasound stimulation (tFUS) including receiving an image of a head of a subject, an acoustic beam profile simulation module configured to generate a subject-specific set of acoustic beam profiles based on the subject's head; subject-specific set of acoustic beam profiles configured to account for acoustic propagation effects through the subject's skull; a planning module coupled to the acoustic beam profile simulation module configured to generate an acoustic intensity scalp map for a target region and to generate a three-dimensional (3D) visualization of a selected beam profile from the subject-specific set of acoustic beam profiles; and a real-time navigation module coupled to the acoustic beam profile simulation module configured to generate a real-time 3D visualization of an acoustic beam for tFUS for a current position of a transducer around the head of the subject based on current position data and the subject-specific set of acoustic beam profiles.
Systems and methods are provided that include acquiring, at a plurality of different times, an induced voltage within a plurality of coils arranged about the subject's head and positioned within a variable magnetic field. The method also includes acquiring electroencephalogram (EEG) data from a plurality of EEG sensors, wherein each EEG sensor is paired with a respective one of the plurality of coils. The method also includes determining, for each of the plurality of times, a position of each coil in the plurality of coils positioned in the variable magnetic field utilizing the induced voltage at the particular time and using the position of each coil in the plurality of coils to correlate the EEG data with at least one of an anatomical image or a functional image of the head of the subject.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
Systems and methods are provided that permanently modify an airway, such as a nasal airway without surgical intervention. The system to modify an airway can include one or more nasal inserts having different geometries or capable of being configured into different geometries to incrementally adjust bone or cartilage in the nasal airway over an extended period of time.
Provided herein are methods for treating a brachyury-associated cancer or neoplasm, e.g., chordoma, with a type I interferon in a subject in need thereof. The methods further include treating the brachyury-associated cancer or neoplasm with interferon alpha or interferon beta by injection of interferon protein into a subject in need thereof, wherein the interferon can be an interferon polypeptide or an interferon nucleic acid formulated for expression.
Provided herein are methods for diagnosing ALS, or determining risk of developing ALS. The methods include detection of a fusion as described herein. The methods can include detecting genomic fusions, fused transcripts, or fusion proteins (where proteins are produced) as described herein.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
77.
GENETICALLY ENCODED SYSTEMS FOR GENERATING OXYGEN IN LIVING EUKARYOTIC CELLS
C12N 1/38 - Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
The present document relates to microfluidic devices and microfluidic systems for capturing a target of interest. Also described herein are methods of isolating or capturing such targets.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
B01D 15/10 - Selective adsorption, e.g. chromatography characterised by constructional or operational features
Methods of detecting and measuring positron emission for tumor margin assessment are described. The preferential uptake of radiotracers by certain tumor types provides a measurable parameter for distinguishing between healthy and cancerous tissue to enhance tumor margin determination. The methods provide more accurate margin delineation and reduced tissue resection size relative to conventional breast conserving surgery techniques.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
000 magnet and one or more gradient coils, and an imaging radiofrequency coil. A method for manufacturing is provided in which the arrangement of magnetic elements is optimized to produce a target magnetic field within a target scanning volume.
Described herein are systems and methods for improving the performance of and compliance with wearable garments. In some embodiments, a system comprises one or more sensors integrated within a wearable garment. The sensors are configured to generate data responsive to pressure exerted by the wearable garment on a user; and one or more processors coupled to the one or more sensors. The processors are configured to process the generated data to determine a duration of use of the wearable garment by the user; and in response to determining that the duration of use is less than a predetermined duration of use threshold, generating one or more notifications.
An imaging and biopsy device, including: a tethered capsule that is configured to be swallowed; a first optical fiber transmitting an electromagnetic radiation that at least partially impacts an anatomical structure; and a biopsy apparatus configured to collect tissue from the anatomical structure, the electromagnetic radiation at least partially or temporarily impacting the biopsy apparatus, and at least a portion of the first optical fiber and the biopsy apparatus being associated with the tethered capsule.
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
An image may be reconstructed from sensor data, which may include optical imaging data such as diffusion optical tomography ("DOT") data. The sensor data are received by a computer system. A machine learning model is accessed with the computer system, where the machine learning model includes a first subnetwork that receives sensor data as an input and generates an intermediate image as a first output, and a second subnetwork that receives the first output from the first subnetwork and generates an enhanced image as a second output. The sensor data are input to the machine learning model using the computer system, generating an enhanced image as an output. The enhanced image may have higher spatial resolution, reduced noise, or other improved image quality. Structural images may be passed as an additional input to the second subnetwork of the machine learning model to increase the spatial resolution of the enhanced image.
Systems and methods are provided for a hybrid superconducting-permanent magnet MR1 system. Permanent magnet elements may be used to supplement or shape the magnetic field produced by the superconducting windings. The hybrid design may increase field homogeneity or reduce the required bore length, thereby reducing the total system cost.
G01R 33/3815 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using electromagnets with superconducting coils, e.g. power supply therefor
G01R 33/383 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using permanent magnets
G01R 33/385 - Systems for generation, homogenisation or stabilisation of the main or gradient magnetic field using gradient magnetic field coils
86.
COMPOSITIONS AND METHODS FOR REDUCING CELL THERAPY IMMUNOGENICITY
This application provides, in part, methods and compositions for decreasing the immunogenicity of cell therapies (e.g., CAR-T cell therapies) using inhibitors of transporter associated with antigen processing (TAPi) and oligonucleotides that decrease the expression of an immunogenic proteins (e.g., MHC Class I and Class II).
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
A61K 35/12 - Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
C12N 15/00 - Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
e.g.e.g.e.g., a DOTA-chelated 68e.g.transtrans-cyclooctene moiety in its structure). As described herein, the imaging and theranostic methods of this disclosure advantageously allow for rapid corporeal elimination of radionuclides once imaging or theranostic treatment is completed.
C07D 257/02 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The disclosure is directed to methods and compositions for treating cancers characterized by cells comprising chimeric antigen receptors (CARs) that bind CD70 and T-cell engaging antibody molecules (TEAMs) that bind CD33, nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind CD70 and/or TEAMs that bind CD33, and compositions and methods related thereto.
Described herein are compositions comprising zinc fingers and methods of use thereof for the treatment of nucleotide repeat expansion disorders such as Ewing Sarcoma.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
C12N 15/62 - DNA sequences coding for fusion proteins
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
The disclosure relates to methods and kits for detecting tau, e.g., tau that is phosphorylated at amino acid position T181 (pTau181), tau that is phosphorylated at amino acid position T217 (pTau217), and/or total tau. The disclosure further provides methods for distinguishing between individuals whose cognitive condition will remain stable and whose cognitive condition will decline during their lifetime. The disclosure also provides methods for determining the eligibility of individuals for participation in clinical trials for Alzheimer's disease treatments. Also provided are methods for distinguishing between individuals with Alzheimer's disease and non-Alzheimer's dementia, and for monitoring response to treatment for Alzheimer's disease.
Described in various embodiments herein are tiled amplification nucleic acid detection systems and uses thereof. In some embodiments, the nucleic acids amplified and detected are cell free DNA (cfDNA).
The present invention relates to treating neurodegeneration (e.g., a neurodegenerative disorder), enhancing cognitive function, delaying or reducing cognitive decline, enhancing the metabolism, and/or improving memory in patients in need thereof, e.g., patients diagnosed with a neurodegenerative disorder or displaying one or more symptoms of a neurodegenerative disorder (e.g., declining cognitive function) by administering Pla2g2f to a subject or increasing expression of Pla2g2f in a cell of a subject.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
95.
SYSTEMS AND METHODS FOR NONCONTACT ULTRASOUND IMAGING
Systems and methods for non-contact, non-invasive image construction of interior tissue are provided. Electromagnetic (EM) waves maybe used to transmit through a high acoustic material or barrier, such as a bone, where the EM wave is then absorbed and converted to ultrasound (US) or audible band acoustic longitudinal waves or shear waves once past the high acoustic impedance barrier. The EM to acoustic converted waves are generated through thermoelastic mechanisms. This enables acoustic waves to propagate in the soft tissue on the opposing side of the barrier while minimizing reverberation and clutter. The US waves propagate within the tissue and may be measured using a detector, such as coherent lidar or optical band multipixel camera noninvasively outside the tissue. Furthermore, a phased array can be used to steer and shape the acoustic radiation pattern of the acoustic waves in the soft tissue beyond the bone or high acoustic impedance barrier.
A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
A61B 5/0507 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves using microwaves or terahertz waves
96.
SCAFFOLDS FOR MODIFYING IMMUNE CELLS AND THE USES THEREOF
The present invention discloses compositions and methods for modulating the immune system in a subject. The compositions of the present invention comprise a porous scaffold biomaterial comprising active agent. The method of the present invention comprises administering to a subject a scaffold composition comprising active agent, thereby modulating the immune system in a subject.
A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
The present disclosure provides photocleavable rhodamine probes that facilitate live- and fixed-cell immunofluorescence. The ultra-fast spirocyclization of the dye following cleavage depletes the fluorescence signal, enabling cyclic multiplexed imaging.
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
This disclosure provides compounds, pharmaceutical compositions, imaging compositions and methods useful for the diagnosis and/or treatment of neurodegenerative diseases. In particular, this disclosure provides compounds, including radiolabeled compounds, compositions, and methods useful for the diagnosis and/or treatment of neurodegenerative diseases associated with a-synuclein aggregation, such as Parkinson's disease, dementia with Lewy bodies, multiple systems atrophy or prodromal REM sleep behavior disorder.
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
C07C 13/47 - Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with a bicyclo ring system containing ten carbon atoms
C07D 251/14 - Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
An apparatus for directing optical energy onto a sample, including: a difference frequency generation (DFG) laser apparatus; a handpiece optically coupled to at least a portion of the DFG laser apparatus by an optical fiber arrangement; and a controller in operative communication with the DFG laser apparatus and the handpiece, wherein the DFG laser apparatus is configured to generate both ablative and nonablative optical energy, and wherein the handpiece includes at least one of an optical or a micromechanical element configured to generate a first pulse and a second pulse of optical energy, wherein a first amount of at least one of ablative optical energy or nonablative optical energy in the first pulse is different from a second amount of at least one of ablative optical energy or nonablative optical energy in the second pulse, and wherein the controller is configured to direct the first pulse and the second pulse onto a particular location on the sample using the handpiece.
A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
A61B 18/22 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Hand-pieces therefor
100.
COMPOSITIONS AND METHODS FOR ENHANCING INTRA-MITOCHONDRIAL PROTEIN TRANSLATION AND OXIDATIVE PHOSPHORYLATION
The present disclosure relates to treating mitochondrial diseases, cancer and other conditions as a result of reduced oxidative phosphorylation (OXPHOS) activity by overexpressing the METTL17 gene, encoding methyltransferase-like 17. Currently, overexpression of METTL17 to increase its copy number and/or intra-mitochondrial activity has not been indicated as a possible therapeutic for treating mitochondrial disease or other diseases such as cancer or aging related to a decline in OXPHOS activity. A variety of gene therapy approaches are presented for overexpression of METTL17 including, but not limited to, AAV, adenovirus and lentiviral vector expression.
patents
